BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 32961897)

  • 1. Induction of the Antiviral Immune Response and Its Circumvention by Coronaviruses.
    Liu P; Hong Y; Yang B; Shrestha P; Sajjad N; Chen JL
    Viruses; 2020 Sep; 12(9):. PubMed ID: 32961897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
    Shah VK; Firmal P; Alam A; Ganguly D; Chattopadhyay S
    Front Immunol; 2020; 11():1949. PubMed ID: 32849654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
    Azkur AK; Akdis M; Azkur D; Sokolowska M; van de Veen W; Brüggen MC; O'Mahony L; Gao Y; Nadeau K; Akdis CA
    Allergy; 2020 Jul; 75(7):1564-1581. PubMed ID: 32396996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A molecular arms race between host innate antiviral response and emerging human coronaviruses.
    Wong LY; Lui PY; Jin DY
    Virol Sin; 2016 Feb; 31(1):12-23. PubMed ID: 26786772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surviving COVID-19: A disease tolerance perspective.
    Ayres JS
    Sci Adv; 2020 May; 6(18):eabc1518. PubMed ID: 32494691
    [No Abstract]   [Full Text] [Related]  

  • 6. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.
    Park A; Iwasaki A
    Cell Host Microbe; 2020 Jun; 27(6):870-878. PubMed ID: 32464097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2-A Tough Opponent for the Immune System.
    Nasab MG; Saghazadeh A; Rezaei N
    Arch Med Res; 2020 Aug; 51(6):589-592. PubMed ID: 32532524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
    Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
    Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LY6E Restricts Entry of Human Coronaviruses, Including Currently Pandemic SARS-CoV-2.
    Zhao X; Zheng S; Chen D; Zheng M; Li X; Li G; Lin H; Chang J; Zeng H; Guo JT
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32641482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral Evasion of the Complement System and Its Importance for Vaccines and Therapeutics.
    Mellors J; Tipton T; Longet S; Carroll M
    Front Immunol; 2020; 11():1450. PubMed ID: 32733480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses.
    Fung SY; Yuen KS; Ye ZW; Chan CP; Jin DY
    Emerg Microbes Infect; 2020; 9(1):558-570. PubMed ID: 32172672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections.
    Ahmed-Hassan H; Sisson B; Shukla RK; Wijewantha Y; Funderburg NT; Li Z; Hayes D; Demberg T; Liyanage NPM
    Front Immunol; 2020; 11():1979. PubMed ID: 32973803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
    Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
    Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innate immune evasion by SARS-CoV-2: Comparison with SARS-CoV.
    Bouayad A
    Rev Med Virol; 2020 Nov; 30(6):1-9. PubMed ID: 32734714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon Control of Human Coronavirus Infection and Viral Evasion: Mechanistic Insights and Implications for Antiviral Drug and Vaccine Development.
    Zhao X; Chen D; Li X; Griffith L; Chang J; An P; Guo JT
    J Mol Biol; 2022 Mar; 434(6):167438. PubMed ID: 34990653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19).
    Chang FY; Chen HC; Chen PJ; Ho MS; Hsieh SL; Lin JC; Liu FT; Sytwu HK
    J Biomed Sci; 2020 Jun; 27(1):72. PubMed ID: 32498686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 may regulate cellular responses through depletion of specific host miRNAs.
    Bartoszewski R; Dabrowski M; Jakiela B; Matalon S; Harrod KS; Sanak M; Collawn JF
    Am J Physiol Lung Cell Mol Physiol; 2020 Sep; 319(3):L444-L455. PubMed ID: 32755307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interplay between SARS-CoV-2 and the type I interferon response.
    Sa Ribero M; Jouvenet N; Dreux M; Nisole S
    PLoS Pathog; 2020 Jul; 16(7):e1008737. PubMed ID: 32726355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coronaviruses and gastrointestinal diseases.
    Luo X; Zhou GZ; Zhang Y; Peng LH; Zou LP; Yang YS
    Mil Med Res; 2020 Oct; 7(1):49. PubMed ID: 33054860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.